December 3, 2025
News
Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”) on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the “Class Period”), inclusive. Investor Deadline: Investors […]
December 2, 2025
News
Berger Montague, a leading national plaintiffs’ law firm, is pleased to announce the launch of the AAI Appellate Project, a new initiative designed to strengthen the position of pro-enforcement litigants in antitrust appellate proceedings and improve the administration of the antitrust laws. The Project will bring together public-minded appellate experts and create […]
December 1, 2025
News
Berger Montague, a leading national plaintiffs’ law firm, is pleased to announce the of Julia McGrath’s inclusion in the inaugural class of the Premier Class Action Lawyers of Tomorrow award, recognizing exceptional rising stars under 40 who are redefining the frontiers of class action litigation through innovative strategies, landmark victories, and unwavering commitment […]
December 1, 2025
News
Berger Montague, a leading national plaintiffs’ law firm, is proud to announce that the Committee to Support the Antitrust Laws (COSAL) has named Candice Enders, Julia McGrath, Jeremy Gradwohl, and Taylor Hollinger as new Committee Leaders. Starting December 1st: Berger Montague is one of the nation’s preeminent law firms focusing on […]
November 25, 2025
News
Berger Montague advises shareholders of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) about an investigation into Baxter’s Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Baxter’s marketing and sale of its Novum Large Volume Pump (“Novum LVP”). Shareholders […]
November 20, 2025
News
National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Jayud Global Logistics Limited (NASDAQ: JYD) (“Jayud” or the “Company”) on behalf of investors who purchased or otherwise acquired Jayud securities during the period of April 21, 2023 through April 30, 2025 (the “Class […]
November 13, 2025
News
Today, Berger Montague, a leading national plaintiffs’ law firm, and 40 consumer protection, data privacy, and competition groups from 10 states and the District of Columbia submitted an amicus brief in Trump v. Slaughter, a case challenging the President’s attempted firing of Federal Trade Commissioner Rebecca Kelly Slaughter. The brief […]
November 13, 2025
News
National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Stride, Inc. (NYSE: LRN) (“Stride” or the “Company”) on behalf of investors who purchased Stride securities during the period of October 22, 2024 through October 28, 2025 (the “Class Period”). Investor Deadline: Investors who […]
November 12, 2025
News
National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) (“Telix” or the “Company”) on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the “Class Period”). Investor Deadline: Investors […]
November 7, 2025
News
National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit against Six Flags Entertainment Corp. (NYSE: FUN) (“Six Flags” or the “Company”) has been filed on behalf of investors who purchased or acquired Six Flags shares July 1, 2024 through November 5, 2025 (the “Class Period”), including […]
November 5, 2025
News
National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit against Fiserv, Inc. (NYSE: FI) (“Fiserv” or the “Company”) has been filed on behalf of investors who purchased Fiserv shares during the period of July 23, 2025 through October 29, 2025 (the “Class Period”). Investor Deadline: Investors who […]
October 29, 2025
News
Berger Montague PC advises shareholders of Akero Therapeutics, Inc. (“Akero” or the “Company”) about an investigation into the Company and members of its Board of Directors for potential breaches of fiduciary duties and violations of the federal securities laws. Shareholders of Akero may learn more about this investigation by contacting Berger […]